SCHEMBL20092097

SCHEMBL20092097

Cc1nn(C)cc1-c1ccc(N)c(N(C)S(C)(=O)=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.45
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 3/20 0.35
ALK Q9UM73 1/20 0.34
BRD4 O60885 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
MAPT P10636 2/20 0.33
CDK1 P06493 1/20 0.33
CDK2 P24941 1/20 0.33
CDK5 Q00535 1/20 0.33
CDC42BPA Q5VT25 1/20 0.33
SRPK1 Q96SB4 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
COMT P21964 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20092811 0.78 KEAP1 (0.46) TYK2ALOX5APFEN1MAPTPIK3CA
SCHEMBL20092304 0.78 CYP11B2 (0.41) TYK2PRMT5WDR77ALOX5APFEN1
SCHEMBL20092236 0.77 TYK2 (0.45) TYK2PRMT5WDR77PIK3CAPIK3CG
SCHEMBL20093051 0.76 TYK2 (0.44) TYK2ALOX5APFEN1BRD4PIK3C3
SCHEMBL20092864 0.76 TYK2 (0.48) TYK2ALOX5APFEN1BRD4PIK3C3
SCHEMBL20092155 0.76 TYK2 (0.45) TYK2ALOX5APFEN1PIK3C3MEN1
SCHEMBL20092121 0.74 TYK2 (0.46) TYK2ALOX5APFEN1BRD4PIK3C3
SCHEMBL20092567 0.73 TYK2 (0.47) TYK2ALOX5APFEN1PIK3C3MAPT
SCHEMBL20092191 0.71 TYK2 (0.48) TYK2PRMT5WDR77ALOX5APFEN1
SCHEMBL12492749 0.70 ALDH1A1 (0.54) PRMT5WDR77ALDH1A1ALKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
WO-2018075937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885PRMT5 690/4885WDR77 657/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 TYK2 1/4885PRMT5 690/4885WDR77 657/4885
US-10647713-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 TYK2 1/4885PRMT5 690/4885WDR77 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.